Cardiovascular complications in community-acquired pneumonia

Clinical Pulmonary Medicine

Volumn 22, Issue 2, 2015, Pages 62-67

  Krüger, Stefan ^a   Frechen, Dirk ^a  

^a Florence Nightingale Krankenhaus   (Germany)

Author keywords

Cardiovascular disease; Heart failure; Myocardial infarction; Pneumonia; Stroke

Indexed keywords

INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 6; PNEUMOCOCCUS VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ALGORITHM; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMMUNITY ACQUIRED PNEUMONIA; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; INFLUENZA; PATHOPHYSIOLOGY; PATIENT MONITORING; PNEUMOCOCCAL INFECTION; RESPIRATORY TRACT INFECTION; THROMBOCYTE ACTIVATION; VACCINATION;

EID: 84924891271     PISSN: 10680640     EISSN: 15365956     Source Type: Journal    
DOI: 10.1097/CPM.0000000000000080     Document Type: Article

References (64)

1. World Health OrganizationThe top ten causes of death. Available at: http://www.who.int/mediacentre/factsheets/fs310.pdf. Accessed September 4, 2013.
2. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 2002;162:1059-1064.
3. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122:130-141.
4. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA. 1996;275:134-141.
5. Waterer GW, Kessler LA, Wunderink RG. Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med. 2004;169:910-914.
6. Brancati FL, Chow JW, Wagener MM, et al. Is pneumonia really the old man's friend? Two-year prognosis after community-acquired pneumonia. Lancet. 1993;342:30-33.
7. Mortensen EM, Kapoor WN, Chang CH, et al. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis . 2003;37:1617-1624.
8. Koivula I, Sten M, Makela P. Prognosis after community-acquired pneumonia in the elderly: a population-based 12 year follow-up study. Arch Intern Med. 1999;159:1550-1555.
9. Yende S, D'Angelo G, Kellum JA, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008;177:1242-1247.
10. Johnstone J, Eurich DT, Majumdar SR, et al. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore). 2008;87:329-334.
11. Bruns AH, Oosterheert JJ, Cucciolillo MC, et al. Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population. Clin Microbiol Infect. 2011;17:763-768.
12. Yende S, Angus DC, Ali IS, et al. Influence of comorbid conditions on long term mortality after pneumonia in older people. J Am Geriatr Soc. 2007;55:518-525.
13. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
14. Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369.
15. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599-2610.
16. Curb JD, Abbott RD, Rodriguez BL, et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation. 2003;107:2016-2020.
17. Yeaman MR. Platelets in defense against bacterial pathogens. Cell Mol Life Sci. 2010;67:525-544.
18. Kellum JA, Kong L, Fink MP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167:1655-1663.
19. Merx MW, Weber C. Sepsis and the heart. Circulation. 2007;116:793-802.
20. Keatinge WR, Donaldson GC. Cardiovascular mortality in winter. Arctic Med Res. 1995;54(suppl 2):16-18.
21. Crawford VL, McNerlan SE, Stout RW. Seasonal changes in platelets, fibrinogen and factor VII in elderly people. Age Ageing. 2003;32:661-665.
22. Woodhouse PR, Khaw KT, Plummer M, et al. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet. 1994;343:435-439.
23. Meier CR, Jick SS, Derby LE, et al. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet. 1998;351:1467-1471.
24. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611-2618.
25. Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J. 2008;29:96-103.
26. Musher DM, Rueda AM, Kaka AS, et al. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45:158-165.
27. Becker T, Moldoveanu A, Cukierman T, et al. Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. Diabetes Res Clin Pract. 2007;78:392-397.
28. Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2008;47:182-187.
29. Mandal P, Chalmers JD, Choudhury G, et al. Vascular complications are associated with poor outcome in community-acquired pneumonia. QJM. 2011;104:489-495.
30. Corrales-Medina VF, Serpa J, Rueda AM, et al. Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine. 2009;88:154-159.
31. Perry TW, Pugh MJ, Waterer GW, et al. Incidence of cardiovascular events after hospital admission for pneumonia. Am J Med. 2011;124:244-251.
32. Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125:773-781.
33. Zurrú MC, Alonzo C, Brescacín L, et al. Recent respiratory infection predicts atherothrombotic stroke: case-control study in a Buenos Aires healthcare system. Stroke. 2009;40:1986-1990.
34. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011;8:e1001048.
35. Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009;1:153-159.
36. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089-1096.
37. Wayne RA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881-1890.
38. Schembri S, Williamson PA, Short PM, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ. 2013;346:f1235.
39. Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA. 2014;311:2199-2208.
40. Viasus D, Garcia-Vidal C, Manresa F, et al. Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. J Infect. 2013;66:27-33.
41. Spodick DH, Flessas AP, Johnson MM. Association of acute respiratory symptoms with onset of acute myocardial infarction: prospective investigation of 150 consecutive patients and matched control patients. Am J Cardiol. 1984;53:481-482.
42. Clayton TC, Capps NE, Stephens NG, et al. Recent respiratory infection and the risk of myocardial infarction. Heart. 2005;91:1601-1602.
43. Lichtman JH, Fathi A, Radford MJ, et al. Acute, severe noncardiac conditions in patients with acute myocardial infarction. Am J Med. 2006;119:843-850.
44. Aliberti S, Amir A, Peyrani P, et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest. 2008;134:955-962.
45. Naghavi M, Barlas Z, Siadaty S, et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation. 2000;102:3039-3045.
46. Keller T, Weeda VB, van Dongen CJ, et al. Influenza vaccines for preventing coronary heart disease. Cochrane Database Syst Rev. 2008;3:CD005050.
47. Johnstone J, Loeb M, Teo KK, et al. Influenza vaccination and major adverse vascular events in high-risk patients. Circulation. 2012;126:278-286.
48. Lamontagne F, Garant MP, Carvalho JC, et al. Pneumococcal vaccination and risk of myocardial infarction. CMAJ. 2008;179:773-777.
49. Tseng HF, Slezak JM, Quinn VP, et al. Pneumococcal vaccination and risk of acute myocardial infarction and stroke in men. JAMA. 2010;303:1699-1706.
50. Siriwardena AN, Gwini SM, Coupland CA. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ. 2010;182:1617-1623.
51. Hung IF, Leung AY, Chu DW, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis. 2010;51:1007-1016.
52. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-250.
53. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377-382.
54. Krúger S, Ewig S, Kunde J, et al. Pro-atrial natriuretic peptide and pro-vasopressin to predict short- and long-term survival in community-acquired pneumonia. Results from the German competence network CAPNETZ. Thorax. 2010;65:208-214.
55. Krúger S, Ewig S, Giersdorf S, et al. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia. Results from the German competence network CAPNETZ. Am J Respir Crit Care Med. 2010;182:1426-1434.
56. Chalmers JD, Short PM, Mandal P, et al. Statins in community acquired pneumonia: evidence from experimental and clinical studies. Respir Med. 2010;104:1081-1091.
57. Krúger S, Merx MW. Nonuse of statins - a new risk factor for infectious death in cardiovascular patients? Crit Care Med. 2007;35:631-632.
58. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-1402.
59. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004;110:880-885.
60. Hackam DG, Mamdani M, Li P, et al. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006;367:413-418.
61. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalized with pneumonia. Eur Respir J. 2008;31:611-617.
62. Winning J, Reichel J, Eisenhut Y, et al. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets. 2009;20:50-57.
63. Winning J, Neumann J, Kohl M, et al. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med. 2010;38:32-37.
64. Otto GP, Sossdorf M, Boettel J, et al. Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock. Platelets. 2013;24:480-485.